# Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer

> **NIH NIH R01** · LSU HEALTH SCIENCES CENTER · 2021 · $381,499

## Abstract

PROJECT SUMMARY:
For women in the United States, breast cancer is the most common malignancy and the second leading cause
of death. In this application, we focus upon a specific subtype of breast cancer known as triple-negative breast
cancer (TNBC). Compared to other breast cancer subtypes, TNBC is considered more aggressive and extremely
difficult to treat with standard therapies. As a result, it has a high recurrence rate and a high overall mortality rate.
TNBC accounts for up to 20% of all breast cancers, with a higher incidence in ethnic minority populations and
young women (usually <40 years of age). Approximately 70% of patients with advanced TNBC die of disease
recurrence and/or metastasis within 5 years of initial diagnosis. Therefore, there is an urgent need for the medical
community to develop more effective therapeutic options for this deadly disease.
In this project, we will investigate a novel experimental compound, named LG007, for its anti-cancer activity in
TNBC. Of significance, we will utilize robust TNBC Patient-Derived Xenograft (PDX) mouse models to study the
in vivo efficacy of LG007. Our preliminary results demonstrated that LG007 effectively inhibits TNBC tumor
growth and metastasis. Notably, we found that LG007 treatment could robustly shrink large human-derived
TNBC PDX tumors, with a near-complete response. These preliminary results strongly support the premise that
LG007 is a novel and potent drug candidate capable of treating progressive TNBC and associated metastasis.
Furthermore, we demonstrated that LG007 is able to target and regulate miR-10b, a well-known oncogenic
miRNA that promotes tumor development and metastasis. Therefore, we hypothesize that miR-10b is a primary
target of LG007 that is critically involved in the molecular mechanisms of action by which LG007 inhibits tumor
growth and metastasis. Three specific aims are proposed in pursuit of the project’s objective to develop a new
therapy for the treatment of TNBC. In Aim 1, we will determine the mechanistic roles of miR-10b and one of its
targets, NR4A3, in the anti-TNBC activity of LG007. In Aim 2, we will investigate the in vivo efficacy of LG007
utilizing a variety of advanced mouse models that mimic the clinical setting of TNBC and its associated
recurrence and metastasis. In Aim 3, we will characterize the pharmacological and toxicological properties of
LG007 in preparation for future translation to clinical testing. We expect that the results obtained from this study
will lead to the development of a novel, safe, and effective treatment for patients with advanced TNBC.

## Key facts

- **NIH application ID:** 10313128
- **Project number:** 1R01CA260698-01A1
- **Recipient organization:** LSU HEALTH SCIENCES CENTER
- **Principal Investigator:** Yaguang Xi
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $381,499
- **Award type:** 1
- **Project period:** 2021-09-01 → 2026-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10313128

## Citation

> US National Institutes of Health, RePORTER application 10313128, Developing LG007 as a novel therapeutic agent to treat triple negative breast cancer (1R01CA260698-01A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10313128. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*